SVB Leerink Maintains Outperform on Amryt Pharma, Raises Price Target to $10
SVB Leerink analyst Mani Foroohar maintains Amryt Pharma (NASDAQ:AMYT) with a Outperform and raises the price target from $9 to $10.
Amryt Pharma’s Q4 FY21 Sales, FY22 Guidance Shy Of Street Consensus
Amryt Pharma Plc’s (NASDAQ:AMYT) Q4 FY21 sales increased 29% Y/Y to $54.8 million, missing the consensus of $56.81 million. The…
Recap: Amryt Pharma Q4 Earnings
Amryt Pharma (NASDAQ:AMYT) reported its Q4 earnings results on Wednesday, March 9, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
UPDATE: Amryt Pharma Q4 EPS $(0.07) Beats $(0.15) Estimate, Sales $54.83M Miss $56.81M Estimate
Amryt Pharma (NASDAQ:AMYT) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.15) by 53.33 percent. This is a 75 percent increase over losses of $(0.28) per share from the
Earnings Scheduled For March 9, 2022
Companies Reporting Before The Bell
• REV Group (NYSE:REVG) is expected to report quarterly earnings at $0.11 per share on revenue of $529.44 million.
A Preview Of Amryt Pharma’s Earnings
Amryt Pharma (NASDAQ:AMYT) is set to give its latest quarterly earnings report on Wednesday, 2022-03-09. Here's what investors need to know before the announcement.
Analysts estimate that Amryt Pharma will report an earnings per share (EPS) of $-0.15.
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB) retreated in four out of five sessions of the week.
42 Stocks Moving In Monday’s Mid-Day Session
Gainers
Mullen Automotive, Inc. (NASDAQ: MULN) jumped 74.4% to $1.20 after the company reported progress on solid-state polymer battery pack development.
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the holiday-shortened week before making a comeback.